drugset
Drugs / TAG Vaccine
last change May 2019 re-read 3 minutes ago

TAG Vaccine

also known as TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine

Vaccine targets TGFB2 via inhibition

Developed for
metastatic carcinoma
Investigated by
Mary Crowley Medical Research Center

Trials 1

today NCT00684294 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00684294 May 2008 → May 2009 metastatic carcinoma Mary Crowley Medical Research Center Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TAG Vaccine “TAG Vaccine 1 x 10^7 cells/ injection” NCT00684294 ↗
Known as TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine “TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine” NCT00684294 ↗
Action Inhibit “TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site.” NCT00684294 ↗
Modality Vaccine “Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer” NCT00684294 ↗
Route Other “via intradermal injection” NCT00684294 ↗
Target TGFB2 “TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site.” NCT00684294 ↗